Puma Biotechnology Inc. Stock
€2.84
Your prediction
Description Puma Biotechnology
Puma Biotechnology is a publicly-traded biopharmaceutical company that focuses on the development and commercialization of innovative treatments for cancer. The company was founded in 2010 and is based in Los Angeles, California, United States.
Puma Biotechnology's flagship product is called Nerlynx (neratinib), which is a tyrosine kinase inhibitor used for the treatment of HER2-positive breast cancer. Nerlynx is now approved for sale in the US, Europe, and other countries.
Puma Biotechnology also has other drugs in development, including PB272 (neratinib) for the treatment of HER2-mutated solid tumors and PB357 (napabucasin) for the treatment of cancer stem cells.
Puma Biotechnology is listed on the NASDAQ stock exchange under the ticker symbol PBYI. The company has a market capitalization of around $856 million as of August 2021.
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Not a member yet? Sign up for free!
Financial data and news for Puma Biotechnology
sharewise wants to provide you with the best news and tools for Puma Biotechnology, so we directly link to the best financial data sources.
Financials
News
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on June 2, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Puma Biotechnology Reports First Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2025. Unless otherwise stated, all comparisons are for the
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on May 5, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, May 8, 2025, following the release of its first quarter
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on April 1, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that clinical data on neratinib will be presented at the American Association for Cancer Research (AACR) Annual
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of an inducement
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons
Puma Biotechnology to Present at TD Cowen’s 45th Annual Health Care Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 27, 2025, following the release of its fourth
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 2, 2025, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement